Million-Scale 3D CRISPR Tumor Variant Screening Reveals Clinically Actionable PTEN–NRF2 Synthetic Lethality
- MCAT™ enables million-scale 3D CRISPR tumor variant screening to systematically identify synthetic lethal, sensitizing, or resistant genetic alterations for clinical assets
- Screening of an NRF2-pathway inhibitor revealed PTEN loss as a clinically actionable synthetic lethal biomarker through a ROS-overload mechanism in PTEN-deficient tumors
- Validation across PTEN-loss PDX models supports clinical translation and initiation of a Phase 1b basket trial, demonstrating the platform’s utility for precision biomarker discovery